1986
|
Sign up to set email alerts
|

Abstract: Fourteen patients with hematologic neoplasia (11 acute myeloid leukemias, 2 non-Hodgkin’s lymphomas and 1 blast crisis of chronic myeloid leukemia) who underwent high-dose cytosine arabinoside (HIDARAC) therapy with or without sequential asparaginase (ASNase) were investigated in order to evaluate liver toxicity and a possible decrease in antithrombin III (AT III) plasma level. AT III was found decreased only in patients who received ASNase, whereas HIDARAC alone did not influence AT III levels. It is pointed … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

1
2
0

Year Published

1990
1990
2021
2021

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 9 publications
(3 citation statements)
references
References 6 publications
(8 reference statements)
1
2
0
Order By: Relevance
“…In contrast to corticosteroids, a further influence of cytosine arabinoside on coagulation has not been described so far. This was also confirmed by some human and in vitro studies [ 21 23 ]. Moreover, a negative effect on wound healing or rather an antiproliferative effect due to the administration of cytarabine was only demonstrated on ocular tissues in vitro and in vivo (rabbits) [ 24 , 25 ].…”
Section: Discussionsupporting
confidence: 76%
“…In contrast to corticosteroids, a further influence of cytosine arabinoside on coagulation has not been described so far. This was also confirmed by some human and in vitro studies [ 21 23 ]. Moreover, a negative effect on wound healing or rather an antiproliferative effect due to the administration of cytarabine was only demonstrated on ocular tissues in vitro and in vivo (rabbits) [ 24 , 25 ].…”
Section: Discussionsupporting
confidence: 76%
“…Most of these data have been obtained in patients receiving a total dosage of 120,000-140,000 IJlm2 over 10-14 days. Nevertheless, it is noteworthy that the haemostatic alterations occur after a few administrations of L-asparaginase (4,7,10,14, 15) and we have previously reported that AT III can be substantially lowered even by a single administration of L-asparaginase 6,000 l)lmz (20). Thus, is not surprising that a considerable prevalence of severe thrombotic events (10 of 238 patientS, 4 .2%) occur also adopting relatively low dosage of asparaginase, such as in the protocol here reporte d (42,000 U/mZ over 7 days) (21).…”
Section: Discussionmentioning
confidence: 99%
“…Depletion of antithrombin 111 (Anderson et al, 1979;Buchanan & Holtkamp, 1980;Liebman et al, 1982;Marra et a/, 1986), and of protein C (Barbui et a/, 1984;Conard et a/, 1985;Vellenga et al, 1985;Pui et a/, 1986), the major inhibitors of blood coagulation, have been reported. In Correspondence: Dr Luigi Gugliotta.…”
mentioning
confidence: 99%